Forte Biosciences, Inc.
$34.43
▲
2.9%
2026-04-21 06:47:01
www.fortebiorx.com
NCM: FBRX
Explore Forte Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$674.68 M
Current Price
$34.43
52W High / Low
$35.8 / $4.9
Stock P/E
—
Book Value
$4.71
Dividend Yield
—
ROCE
-113.91%
ROE
-1.22%
Face Value
—
EPS
$-4.71
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
19
Beta
3.2
Debt / Equity
—
Current Ratio
3.88
Quick Ratio
3.88
Forward P/E
-8.12
Price / Sales
—
Enterprise Value
$581.62 M
EV / EBITDA
-8.24
EV / Revenue
—
Rating
Strong Buy
Target Price
$63.75
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Ionis Pharmaceuticals, Inc. | $74.84 | — | $12.38 B | — | -13.92% | -70.8% | $86.74 / $27.9 | $3 |
| 2. | Aurinia Pharmaceuticals Inc. | $15.96 | 7.38 | $2.12 B | — | 16.2% | 59.91% | $16.54 / $7.29 | $4.39 |
| 3. | Immix Biopharma, Inc. | $10.09 | — | $548.68 M | — | -31.62% | -55% | $11.61 / $1.57 | $1.77 |
| 4. | Pasithea Therapeutics Corp. | $0.72 | — | $18.52 M | — | -37.74% | -58.36% | $3.79 / $0.28 | $2.39 |
| 5. | PMGC Holdings Inc. | $3.32 | — | $6.35 M | — | -76.42% | -1.07% | $309.12 / $1.62 | $97.11 |
| 6. | Contineum Therapeutics, Inc. | $13.47 | — | $524.38 M | — | -25.5% | -26.13% | $16.33 / $3.35 | $6.99 |
| 7. | Tango Therapeutics, Inc. | $26.39 | — | $3.8 B | — | -29.52% | -37.23% | $26.81 / $1.03 | $2.55 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -24.57 M | -18.38 M | -11.58 M | -16.12 M | -7.35 M | — |
| Net Profit | -24.79 M | -17.68 M | -11.25 M | -15.66 M | -7.16 M | — |
| EPS in Rs | -1.79 | -1.27 | -0.81 | -1.13 | -0.52 | -4.54 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -70.66 M | -36.6 M | -32.49 M | -13.9 M |
| Net Profit | -69.38 M | -35.48 M | -31.48 M | -13.88 M |
| EPS in Rs | -5 | -2.56 | -2.27 | -1 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 82.78 M | 61.56 M | 38.98 M | 42 M |
| Total Liabilities | 21.79 M | 9.08 M | 3.67 M | 3.18 M |
| Equity | 60.99 M | 52.48 M | 35.31 M | 38.82 M |
| Current Assets | 80.59 M | 61.35 M | 38.33 M | 41.51 M |
| Current Liabilities | 20.75 M | 9.08 M | 3.67 M | 3.18 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -50.88 M | -30.75 M | -28.71 M | -8.19 M |
| Investing CF | 36.23 M | -35.99 M | 0.05 M | 0 M |
| Financing CF | 69.36 M | 51.86 M | 24.68 M | 7.24 M |
| Free CF | -51 M | -30.78 M | -28.79 M | -8.19 M |
| Capex | -0.12 M | -0.04 M | -0.09 M | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -12.71% | -126.79% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-08-28 | 1:0.04 |